A method for preparing a key intermediate of oxazepam

By using a mixed solution of glacial acetic acid and ketone solvents and potassium permanganate in the preparation process of oxazepam intermediates, the problems of high cost and low purity in the prior art are solved, and high purity and high yield are achieved Preparation simplifies the process flow and reduces environmental pollution.

CN115215809BActive Publication Date: 2024-12-03HUAZHONG PHARMA
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202210921878.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-02
Publication Date
2024-12-03
Estimated Expiration
2042-08-02

AI Technical Summary

Technical Problem

The preparation process of the existing oxazepam key intermediate 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide has high cost, low yield, and products The problem of low purity and environmental pollution is especially due to the use of high-risk hydrogen peroxide and expensive sodium tungstate dihydrate catalysts, and the complex post-treatment process, making it difficult to recover solvents, which affects industrial production.

Method used

A mixture of glacial acetic acid and ketone solvents was used to carry out the acylation-cyclization reaction of 2-amino-5-chloro-benzophenone oxime, and potassium permanganate was added to the reaction, and the pH was adjusted to 3-4 and then water was added to the analysis. The material was filtered, washed and dried, and the target product with high purity was directly obtained, which avoided excessive use and side reactions of glacial acetic acid, and simplified the post-treatment process.

Benefits of technology

Preparation of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide with high purity (99.5% or more) and high yield (91% or more) , reduces production costs, simplifies process flow, reduces impurity generation, and improves product quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115215809B_ABST
    Figure CN115215809B_ABST
Patent Text Reader

Abstract

The invention discloses a method for preparing a key intermediate of oxazepam, wherein the key intermediate is 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide, and the method is specifically as follows: 2-amino-5-chloro-benzophenone oxime is put into a mixed solution, and then chloroacetyl chloride is added to react, and after the reaction is completed, it is concentrated under reduced pressure; the obtained product is subjected to a ring expansion reaction, and after the reaction is completed, the pH is adjusted to 3-4, and then water is added to precipitate the material, and the target product is obtained by washing and drying after filtering; wherein the mixed solution is composed of glacial acetic acid, potassium permanganate and ketone solvents. The process can effectively avoid impurities generated by the removal of coordinated oxygen from the intermediate product, and does not require a purification process, has the advantages of a higher total yield, low production cost, and high product purity, and is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis and relates to a method for preparing a key intermediate of oxazepam, specifically a method for preparing 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide. Background Art

[0002] Oxazepam is a benzodiazepine A sedative hypnotic, it is mainly used clinically to treat anxiety, insomnia, and alcohol withdrawal. The advantages of oxazepam are mainly reflected in: the metabolic process is simple, and it is less affected by age and liver function; it has a short half-life and is not easy to accumulate in the body; it is less addictive, and is especially suitable for patients with mild liver damage and the elderly. 7-Chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide (also known as demozepam) is a key intermediate for the preparation of oxazepam, and is also the oxazepam impurity E specified in the European Pharmacopoeia EP8.0, CAS number: 963-39-3, and its structural formula is as follows: Figure 1 shown.

[0003] There are two main synthetic processes for the oxazepam intermediate 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide. Among them, the first one uses 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one as the starting material to prepare 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one-4-oxide (i.e., another name for 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide). Its mechanism diagram is shown below: Figure 2As shown. For example, in the synthesis process of the document "Quinazolinesand 1,4-Benzodiazepines.IV.Transformations 7-Chloro-2-methylamino-5-phenyl-3H-l,4-benzodiazepine 4-Oxide" (Journal of Organic Chemistry, 1961, 26, 4936-4941), 30% hydrogen peroxide is added to the acetic acid solvent, and after the reaction is completed, it is extracted with dichloromethane, washed with hydrochloric acid, and finally refined with dichloromethane, ether and petroleum ether; the process time is more than 46 hours, there are many reaction by-products, and the reaction needs to be extracted and purified by multiple solvents in batches. Not only is the post-processing cumbersome, but the product yield is only 19%. On this basis, Chinese patent CN104961692A shortens the reaction time, reduces the consumption of hydrogen peroxide, and improves the reaction yield by adding sodium tungstate dihydrate as a catalyst in the oxidation reaction. However, the synthesis process has the following disadvantages: ① The use of hydrogen peroxide oxidation is dangerous, and the temperature of the reaction system will rise sharply during the process of adding hydrogen peroxide and keeping warm after adding hydrogen peroxide, which makes it difficult to control the temperature, resulting in large impurities in the target product and low yield of the process; ② Sodium tungstate dihydrate is expensive and difficult to recover after the reaction; ③ In the post-treatment process, in order to promote the complete precipitation of the target product and thoroughly wash away the catalyst sodium tungstate dihydrate, a large amount of water needs to be added, thereby increasing the burden of industrial production wastewater treatment; ④ A large amount of dichloromethane is needed to extract the product, which has a low boiling point and is difficult to recover, and after dichloromethane is evaporated, it is still necessary to recrystallize in ethanol solvent to obtain the target product, further reducing the yield of the process; ⑤ The genotoxic substance formaldehyde is also needed in the stage of decomposing excess hydrogen peroxide, which will not only harm the production site environment, but also have an adverse impact on the quality research and market sales of the finished product.

[0004] The second process for synthesizing 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide is the mainstream method in current production. Its synthetic route is as follows: Figure 3As shown, specifically: 2-amino-5-chloro-benzophenone is used as a raw material, and hydroxylamine hydrochloride is used for oximation to obtain 2-amino-5-chloro-benzophenone oxime; 2-amino-5-chloro-benzophenone oxime and chloroacetyl chloride are first subjected to acylation reaction in glacial acetic acid solvent, and during the acylation reaction, cyclization is carried out under the action of glacial acetic acid to generate 2-chloromethyl-4-phenyl-6-chloroquinazoline-3-oxide (referred to as 3-oxide); finally, ring expansion is carried out under the action of sodium hydroxide to obtain 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide (referred to as 4-oxide), wherein the amount ratio of 2-amino-5-chloro-benzophenone oxime to glacial acetic acid is 1g:2.27ml. In this process, glacial acetic acid is used as the reaction solvent, so the post-treatment process after the cyclization reaction needs to be concentrated and evaporated to remove the glacial acetic acid; and because the thermal stability of 3-oxide is poor, the amount of glacial acetic acid used in the process is relatively large, and the boiling point of glacial acetic acid is as high as 118°C, which leads to a long concentration time and a high system temperature during concentration. Even under conditions of high vacuum, impurities will still be generated, which will affect the purity of the target product 4-oxide. The existing preparation process usually purifies the crude 4-oxide through ethanol beating, but the liquid phase purity after purification is only about 95%, and the beating purification further reduces the yield level. In addition to the impurities generated in the post-treatment process, the acylation-cyclization reaction process is also prone to produce impurities. For example Figure 4 As shown: During the cyclization reaction and reduced pressure concentration steps, due to the free reducing substances present in glacial acetic acid, the reducing substances will remove the coordinated oxygen of the 3-oxide to generate impurity I, which will further participate in the ring expansion reaction to generate impurity II (7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one). Since impurity II has a similar structure and polarity to the target product 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide, it is difficult to remove it using conventional recrystallization or pulping purification processes. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a preparation process of a key intermediate of oxazepam (i.e., 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide) suitable for industrial production, which has high yield, low production cost and product purity of more than 99.5%.

[0006] In order to solve the above problems, the technical solutions of the present invention are as follows:

[0007] A method for preparing a key intermediate of oxazepam, wherein the key intermediate is 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide, specifically comprising the following steps:

[0008] Step 1, adding 2-amino-5-chloro-benzophenone oxime into a mixed solution, and then adding chloroacetyl chloride to react, and after the reaction is completed, concentrating under reduced pressure; the mixed solution consists of glacial acetic acid, potassium permanganate and a ketone solvent;

[0009] Step 2: Perform a ring expansion reaction on the product obtained in step 1. After the reaction is completed, adjust the pH to 3-4, then add water to precipitate the material, filter, wash and dry to obtain the target product.

[0010] Furthermore, in the above technical solution, the volume ratio of glacial acetic acid to ketone solvent in the mixed solution is 1:3-5.

[0011] Furthermore, in step 1, the mass volume ratio of 2-amino-5-chloro-benzophenone oxime, glacial acetic acid, ketone solvent and potassium permanganate is 1g:0.4-0.6ml:1.8-2.0ml:0.001-0.003g.

[0012] Furthermore, in the above technical solution, the ketone solvent is acetone and / or butanone.

[0013] Furthermore, in the above technical solution, the mass ratio of chloroacetyl chloride to 2-amino-5-chloro-benzophenone oxime is 0.7 to 1:1.

[0014] Further, in the above technical scheme, the ring-expansion reaction in step 2 is specifically as follows: adding the product obtained in step 1 to a reaction solution consisting of sodium hydroxide, water and ethanol for reaction; further, the reaction temperature is 15° C. to 20° C.; the mass volume ratio of sodium hydroxide, water and ethanol in the reaction solution is 1 g: 0.9 to 1.2 ml: 7 to 9 ml, wherein the mass ratio of sodium hydroxide to 2-amino-5-chloro-benzophenone oxime is 1:1.

[0015] Furthermore, in the above technical solution, when adjusting the pH, the regulator used may be a hydrochloric acid aqueous solution; further, the mass percentage concentration of the hydrochloric acid aqueous solution is ≥18%.

[0016] Furthermore, in the above technical solution, during the process of adding water to separate the materials, the ratio of the amount of water added to 2-amino-5-chloro-benzophenone oxime is 8-10 ml:1 g.

[0017] Furthermore, in the above technical solution, the reaction process of step one is specifically as follows: first, chloroacetyl chloride is added dropwise to the mixed solution at 40°C to 50°C, and after the addition is completed, the temperature is raised to 50°C to 55°C for reaction.

[0018] Compared with the prior art, the beneficial effects of the present invention are:

[0019] 1) The present invention uses a mixed solution of glacial acetic acid and ketone to carry out the acylation-cyclization reaction of 2-amino-5-chloro-benzophenone oxime, which not only greatly reduces the amount of glacial acetic acid used, but also helps to shorten the concentration time and reduce the concentration temperature in the post-reaction treatment to reduce the generation of impurities in the concentration stage, which is beneficial to the material safety of the unstable intermediate product 2-chloromethyl-4-phenyl-6-chloroquinazoline-3-oxide;

[0020] 2) adding a trace amount of potassium permanganate to the mixed solution system in the acylation-cyclization reaction of 2-amino-5-chloro-benzophenone oxime is beneficial to prevent the free reducing substances present in glacial acetic acid from removing the coordinated oxygen of the intermediate product 2-chloromethyl-4-phenyl-6-chloroquinazoline-3-oxide during the reaction to generate 2-chloromethyl-4-phenyl-6-chloroquinazoline impurity (i.e., impurity I), thereby preventing the 7-chloro-5-phenyl-1,4-benzodiazepine-2-one impurity (i.e., impurity II) from appearing in the target product, and at the same time effectively avoiding the side reaction between the ketone solvent used in the mixed solution system and chloroacetyl chloride due to enolization;

[0021] 3) The preparation method provided by the present invention does not require a purification step and can directly obtain the target product 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide with a purity of not less than 99.5%, which is higher than the purity standard (95.0%) of the prior art; and the yield is as high as more than 91%, which is more than 26 percentage points higher than the yield of the prior art (63% to 65%). BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is the structural formula of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide;

[0023] Figure 2 The diagram is a mechanism diagram for the synthesis of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide by hydrogen peroxide oxidation;

[0024] Figure 3 A route map for the synthesis of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide using 2-amino-5-chloro-benzophenone as a starting material;

[0025] Figure 4 The diagram is a mechanism diagram of the generation of impurities from the intermediate product 3-oxide during the reaction;

[0026] Figure 5 A synthetic route diagram of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide provided by the present invention;

[0027] Figure 6 The HPLC spectrum of the final product prepared in Example 1;

[0028] Figure 7 The HPLC spectrum of the final product prepared in Example 2;

[0029] Figure 8 The HPLC spectrum of the final product prepared in Example 3;

[0030] Fig. 9 The HPLC spectrum of the final product prepared in Comparative Example 1. DETAILED DESCRIPTION

[0031] The technical solution of the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. It should be understood that the specific implementation methods described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0032] In the following examples, unless otherwise specified, all methods are conventional methods; the reagents and materials described, unless otherwise specified, can be obtained from commercial sources.

[0033] Example 1

[0034] The preparation process of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in this embodiment is as follows:

[0035] Add 40ml of glacial acetic acid, 200ml of acetone and 0.1g of potassium permanganate to the reaction bottle in sequence, and stir at room temperature for 10 minutes. Then add 100g of 2-amino-5-chloro-diphenyl ketone oxime, stir and heat to 40°C, add 80g of chloroacetyl chloride dropwise, and control the temperature of chloroacetyl chloride dropwise between 40°C and 50°C. After the addition, maintain the temperature of the reaction system between 50°C and 55°C, stir and react for 2 hours, and then continue to stand and react at this temperature for 2 hours. Concentrate under reduced pressure to remove the organic solvent, and add a mixed solution prepared by 100g of sodium hydroxide, 100ml of water and 800ml of ethanol to the residue remaining after the concentration under reduced pressure while stirring, maintain the solution temperature between 15°C and 20°C and stir for 1 hour. Cool down to 5°C, add 18% hydrochloric acid aqueous solution by mass concentration to adjust the pH to 3-4. Then 800 ml of water was added and stirred for 1 hour, filtered, washed with water, and dried to obtain 106.5 g of the final product with a yield of 91.6%.

[0036] The final product was tested by HPLC. Figure 6 As shown: the purity of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in the final product is 99.9%.

[0037] Example 2

[0038] The preparation process of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in this embodiment is as follows:

[0039] Add 60ml of glacial acetic acid, 180ml of butanone and 0.3g of potassium permanganate to the reaction bottle in sequence, and stir at room temperature for 10 minutes. Then add 100g of 2-amino-5-chloro-diphenyl ketone oxime, stir and heat to 40°C, add 83g of chloroacetyl chloride dropwise, and control the temperature of chloroacetyl chloride dropwise between 40°C and 50°C. After the addition, maintain the temperature of the reaction system between 50°C and 55°C, stir and react for 2 hours, and then continue to stand and react at this temperature for 2 hours. Concentrate under reduced pressure to remove the organic solvent, add a mixed solution pre-configured with 100g of sodium hydroxide, 100ml of water and 800ml of ethanol to the residue remaining after concentration under reduced pressure while stirring, maintain the solution temperature between 15°C and 20°C and stir for 1 hour. The temperature was lowered to 5°C, 18% by mass concentration of hydrochloric acid aqueous solution was added to adjust the pH to 3-4, 1000 ml of water was added and stirred for 1 hour, filtered, washed with water, and dried to obtain 107.3 g of the final product with a yield of 92.3%.

[0040] The final product was tested by HPLC. Figure 7 As shown: the purity of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in the final product is 99.7%.

[0041] Example 3

[0042] The preparation process of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in this embodiment is as follows:

[0043] Add 50ml of glacial acetic acid, 200ml of acetone and 0.2g of potassium permanganate to the reaction bottle in sequence, and stir at room temperature for 10 minutes. Then add 100g of 2-amino-5-chloro-benzophenone oxime, stir and heat to 40°C, add 85g of chloroacetyl chloride dropwise, and control the temperature of chloroacetyl chloride dropwise between 40°C and 50°C. After the addition, maintain the temperature of the reaction system between 50°C and 55°C, stir and react for 2 hours, and then continue to stand and react at this temperature for 2 hours. Concentrate under reduced pressure to remove the organic solvent, add a mixed solution prepared by 100g of sodium hydroxide, 100ml of water and 800ml of ethanol to the residue remaining after concentration under reduced pressure while stirring, maintain the solution temperature between 15°C and 20°C and stir for 1 hour. The temperature was lowered to 5°C, 18% by mass concentration of hydrochloric acid aqueous solution was added to adjust the pH to 3-4, and then 900 ml of water was added and stirred for 1 hour, filtered, washed with water, and dried to obtain 108.1 g of the final product with a yield of 93.0%.

[0044] The final product was tested by HPLC. Figure 8As shown: the purity of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in the final product is 99.8%.

[0045] Comparative Example 1

[0046] The preparation process of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in this embodiment is as follows:

[0047] Add 220ml of glacial acetic acid and 100g of 2-amino-5-chloro-dibenzophenone oxime to the reaction bottle in sequence, stir and heat to 40℃, add 90g of chloroacetyl chloride dropwise, and control the temperature of chloroacetyl chloride dropwise between 40℃ and 50℃. After the addition, maintain the temperature of the reaction system between 50℃ and 55℃ and stir for 1 hour, and then continue to stand at this temperature for 6 hours. Concentrate under reduced pressure to remove the organic solvent, add a mixed solution prepared by 100g of sodium hydroxide, 100ml of water and 800ml of ethanol to the residue remaining after the concentration under reduced pressure, maintain the solution temperature between 15℃ and 20℃ and stir for 1 hour. Add a hydrochloric acid aqueous solution with a mass percentage concentration of 18% to adjust the pH to 3-4, then add 1000ml of water and stir for 1 hour, filter, wash with water, rinse with 50ml of ethanol, and obtain a crude product of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide.

[0048] Then, 260 ml of ethanol was added to the crude product of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide, and the mixture was refluxed and slurried for purification, and dried to obtain 75.5 g of the final product with a yield of 65.0%.

[0049] The final product was tested by HPLC. Fig. 9 As shown: the purity of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in the final product is 95.7%.

[0050] Comparative Example 2

[0051] The preparation process of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in this embodiment is as follows:

[0052] Add 40ml of glacial acetic acid and 200ml of acetone to the reaction bottle in sequence, and stir at room temperature for 10 minutes. Then add 100g of 2-amino-5-chloro-benzophenone oxime, stir and heat to 40°C, add 80g of chloroacetyl chloride dropwise, and control the temperature of chloroacetyl chloride dropwise between 40°C and 50°C. After the addition, maintain the temperature of the reaction system between 50°C and 55°C and stir the reaction for 2 hours, and then continue to stand at this temperature for 2 hours. Concentrate under reduced pressure to remove the organic solvent, and add a mixed solution prepared by 100g of sodium hydroxide, 100ml of water and 800ml of ethanol to the residue remaining after concentration under reduced pressure while stirring, and maintain the solution temperature between 15°C and 20°C and stir for 1 hour. The temperature was lowered to 5°C, and a hydrochloric acid aqueous solution with a mass percentage concentration of 18% was added to adjust the pH to 3-4, and then 800 ml of water was added and stirred for 1 hour, filtered, washed with neutral water, and rinsed with 50 ml of ethanol to obtain a crude product of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide.

[0053] Then, 300 ml of ethanol was added to the crude product of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide, and the mixture was refluxed and slurried for purification, and dried to obtain 93.1 g of the final product with a yield of 80.1%.

[0054] The final product was detected by HPLC, and the result showed that the purity of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide in the final product was 95.9%.

[0055] The raw materials listed in the present invention, as well as the upper and lower limits and interval values ​​of the raw materials of the present invention, and the upper and lower limits and interval values ​​of the process parameters can all realize the present invention, and the embodiments are not listed one by one here.

[0056] In addition, compared with Example 1 and Example 3, the types and contents of impurities in Example 2 are slightly increased. In Example 2, glacial acetic acid and butanone are used for the reaction. Since the boiling point of butanone is higher than that of acetone by more than 20°C, the system temperature will be higher than that of the glacial acetic acid and acetone system at the stage of reduced pressure concentration and distillation of the organic solvent at the end of the reaction. The increase in the concentration temperature will increase the risk of introducing impurities into the product during the concentration process; in the post-treatment stage of the ring expansion reaction, although increasing the amount of water separation to a certain extent is conducive to the precipitation of the target product, it will also cause the target product to contain more impurity components.

[0057] In summary, the preparation process of 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide provided by the present invention not only has a simple production process, low cost and high yield, but also can significantly reduce the impurity content in the final product, and has great application value.

[0058] The present invention is not limited to what is described in the specification and implementation modes, and therefore additional advantages and modifications can be easily realized by those skilled in the art. Therefore, without departing from the spirit and scope of the general concept defined by the claims and their equivalents, the present invention is not limited to the specific details, representative devices, and examples shown and described herein.

Claims

1. A method for preparing a key intermediate of oxazepam, wherein the key intermediate is 7-chloro-2-oxo-5-phenyl-1,4-benzodiazepine-4-oxide, characterized in that: The following steps are involved: Step 1, adding 2-amino-5-chloro-benzophenone oxime into a mixed solution, and then adding chloroacetyl chloride to react, and after the reaction is completed, concentrating under reduced pressure; the mixed solution consists of glacial acetic acid, potassium permanganate and a ketone solvent; Step 2: performing a ring expansion reaction on the product obtained in step 1. After the reaction is completed, adjusting the pH to 3-4, then adding water to precipitate the material, filtering, washing and drying to obtain the target product; the mass volume ratio of the 2-amino-5-chloro-benzophenone oxime, glacial acetic acid, ketone solvent and potassium permanganate is 1g:0.4-0.6ml:1.8-2.0ml:0.001-0.003g, and the ketone solvent is acetone and / or butanone.

2. The method for preparing the key intermediate of oxazepam according to claim 1, characterized in that: The ring-expansion reaction in step 2 is specifically as follows: adding the product obtained in step 1 into a reaction solution consisting of sodium hydroxide, water and ethanol to react.

3. The method for preparing the key intermediate of oxazepam according to claim 1, characterized in that: In the process of adjusting pH in step 2, the adjusting agent used is aqueous hydrochloric acid solution.

4. The method for preparing the key intermediate of oxazepam according to claim 3, characterized in that: The mass percentage concentration of the hydrochloric acid aqueous solution is ≥18%.

5. The method for preparing the key intermediate of oxazepam according to claim 1, characterized in that: In the process of adding water to separate the materials in step 2, the ratio of the amount of water added to 2-amino-5-chloro-benzophenone oxime is 8-10 ml:1 g.

6. The method for preparing the key intermediate of oxazepam according to claim 1, characterized in that: The reaction process of step 1 is specifically as follows: chloroacetyl chloride is added dropwise to the mixed solution at 40°C to 50°C, and after the addition is complete, the temperature is raised to 50°C to 55°C for reaction.

7. The method for preparing the key intermediate of oxazepam according to claim 2, characterized in that: The temperature of the ring expansion reaction is 15°C to 20°C.

Citation Information

Patent Citations

  • Improved preparation method of 7-chlorin-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-keto-4-oxide

    CN104961692A

  • Preparation method of lorazepam intermediate

    CN112028844A

  • Preparation method of lorazepam intermediate

    CN112500359A

  • Hydroxy benzodiazepine derivs with sedative - activity

    DE2043614A1

  • A procedure for the obtaining of hydroxyl derivatives and their benzodiazepin esters.

    ES386050A1